Fig. 2.

11β-HSD1 ASO treatment decreased fasting plasma levels of LDL cholesterol, HDL cholesterol, and plasma apoAI. Expression of apoAI and several ABC transporters was also reduced. A: Plasma samples from 10 mice in each treatment group were pooled for FPLC separation of lipoproteins using two Superose 6 columns in series. B: Plasma apoAI was determined by immunoblotting with mouse β-ACTIN as an internal control. A representative Western blot is shown. C: Genes related to cholesterol metabolism were determined using QPCR and normalized by β-ACTIN mRNA. Data are presented as means ± SEM (n = 10-20 per group). *P < 0.05, **P < 0.01, 11β-HSD1 versus control; ^#P < 0.05, ^##P < 0.01, 11β-HSD1 versus FMC.